Towa International expands its capabilities with a new high containment area at its Barcelona plant

• The company has invested more than 9 million euros in the creation of a new high containment area at its plant in Martorelles, Barcelona, which will handle the production of highly potent substances.
• The expansion, which is part of the 2024-2026 strategic plan, is in addition to the €20 million already invested since the creation of Towa International in 2020.
• With this new facility, which will be operational in the first quarter of 2026, the Martorelles plant, one of the largest in Europe, will significantly expand its production capacity.

Barcelona, September 25, 2024. Towa International, an international pharmaceutical holding company specializing in the research, development, manufacture, marketing and distribution of generic and value-added medicines, which distributes directly in Europe and the United States through its commercial subsidiaries, Towa Pharmaceutical and Breckenridge Pharmaceutical, and in more than 30 countries through its Towa2B business unit, has announced the expansion of its plant in Martorelles, Barcelona, with a new high-containment area designed to handle the production of highly potent substances. With an investment of more than €9 million, which adds to the €20 million already invested since the creation of Towa International in 2020, the company reinforces its commitment to expanding its production and R&D capabilities, as well as boosting its internationalization process.

According to David Peix, CEO of Towa International, “This investment is part of our consolidated 2024/2026 strategic plan, in which we reaffirm our objective to continue expanding our production and R&D capabilities. Our aim is to make these advances available to our customers and to reach the largest number of patients worldwide, as part of our ongoing commitment to internationalization.”

The Martorelles plant, one of the largest in Europe with more than 35.000 m², will incorporate a new high containment area of more than 600 m², which will allow the manufacture of batches of between 10 and 100 kg of highly potent substances. This new space will be equipped with advanced technology for the manufacture of solid forms: tablets, coated tablets and capsules. The design of the facilities and the technology implemented ensure a safe environment for both workers and the drugs manufactured there, avoiding cross-contamination and the release of hazardous substances into the environment, while maintaining the high standards of quality and sustainability that are a priority for the company.

With this expansion, the Martorelles plant will reach 5.6 billion doses per year and will consolidate its position as a reference center for the manufacture of high potency drugs. The new area will be fully operational in the first quarter of 2026, positioning Towa International as one of the few pharmaceutical companies with the capacity to develop and produce high potency drugs in a specialized production plant and R&D center, thus offering a wider range of options to its customers.

Pablo Magnani, Chief Operating Officer of Towa International, said: “This investment will enable us to continue to meet the growing demand for high potency handling solutions, ensuring our customers have access to the capabilities they will need both now and in the future. In addition, the new area will offer us the opportunity to develop and manufacture oncology products, reinforcing our commitment to serving the needs of all our customers and patients.”

With this investment and the recent addition of the new CMO/CDMO line, Towa International reaffirms its commitment to the continuous improvement of its infrastructure and processes and reinforces its position as a leader in the generics market.